Categories: NewsPharmaceutical

Aytu BioPharma to Present at LD Micro Main Event XVI Conference

ENGLEWOOD, CO / ACCESSWIRE / September 13, 2023 / Aytu BioPharma, Inc. (the Company or “Aytu”) (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its CEO, Josh Disbrow, and CFO, Mark Oki, will be will be participating in the LD Micro Main Event XVI Conference, being held on October 3-5, 2023, at Luxe Sunset Boulevard Hotel in Los Angeles.

Management will present on Wednesday, October 4th at 10:00am PT. A webcast link to listen to the presentation can be found on the investor relations page of the Company’s website or accessed HERE. Management will also host one-on-one investor meetings on October 3rd and 4th.

To request a meeting with the Aytu management team, please contact your respective LD Micro representative or email the Company’s investor relations team at AYTU@lythampartners.com.

About Aytu BioPharma, Inc.

Aytu BioPharma is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. The Company’s prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Aytu’s consumer health segment markets a range of over-the-counter medicines and consumer health products addressing a range of common conditions including diabetes, allergy, hair regrowth, and gastrointestinal conditions. To learn more, please visit aytubio.com.

Contacts for Investors:

Mark Oki, Chief Financial Officer
Aytu BioPharma, Inc.
moki@aytubio.com

Robert Blum or Roger Weiss
Lytham Partners
AYTU@lythampartners.com

SOURCE: Aytu BioPharma, Inc.

View source version on accesswire.com:
https://www.accesswire.com/782823/aytu-biopharma-to-present-at-ld-micro-main-event-xvi-conference

Staff

Recent Posts

Invitation to Cosmo’s Half-Year 2024 Webcast on 24 July 2024

Dublin, Ireland--(Newsfile Corp. - July 9, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43)…

13 mins ago

Rosen Law Firm Urges SeaStar Medical Holding Corporation (ICU, ICUCW) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder…

2 hours ago

Best Rated San Antonio Plastic Surgeons for 2024 (Q1) Research Report Released by Doctor Marketing, MD

The Review Growth Index™ (RGI™) by Doctor Marketing, MD™ releases the researched list of Top…

2 hours ago

Newport Beach Plastic Surgeon Corrects Other Surgeons’ Mistakes

Many patients turn to Dr. Brandon Richland, MD, an expert board-certified plastic surgeon in Newport…

2 hours ago

Richland Aesthetics, Newport Beach’s Luxury Med Spa

Richland Aesthetics in Newport Beach, CA introduces state-of-the-art medspa treatments in a serene, luxurious setting,…

5 hours ago